391 related articles for article (PubMed ID: 19414558)
1. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.
Hirschhorn-Cymerman D; Rizzuto GA; Merghoub T; Cohen AD; Avogadri F; Lesokhin AM; Weinberg AD; Wolchok JD; Houghton AN
J Exp Med; 2009 May; 206(5):1103-16. PubMed ID: 19414558
[TBL] [Abstract][Full Text] [Related]
2. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
Piconese S; Valzasina B; Colombo MP
J Exp Med; 2008 Apr; 205(4):825-39. PubMed ID: 18362171
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
4. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Bulliard Y; Jolicoeur R; Zhang J; Dranoff G; Wilson NS; Brogdon JL
Immunol Cell Biol; 2014 Jul; 92(6):475-80. PubMed ID: 24732076
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.
Kim YH; Choi BK; Oh HS; Kang WJ; Mittler RS; Kwon BS
Mol Cancer Ther; 2009 Feb; 8(2):469-78. PubMed ID: 19190115
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells.
Kuczma M; Kopij M; Pawlikowska I; Wang CY; Rempala GA; Kraj P
PLoS One; 2010 Oct; 5(10):e13623. PubMed ID: 21049016
[TBL] [Abstract][Full Text] [Related]
7. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
[TBL] [Abstract][Full Text] [Related]
8. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.
Fujiwara S; Nagai H; Shimoura N; Oniki S; Yoshimoto T; Nishigori C
J Invest Dermatol; 2014 Jul; 134(7):1884-1892. PubMed ID: 24468748
[TBL] [Abstract][Full Text] [Related]
10. OX40 is a potent immune-stimulating target in late-stage cancer patients.
Curti BD; Kovacsovics-Bankowski M; Morris N; Walker E; Chisholm L; Floyd K; Walker J; Gonzalez I; Meeuwsen T; Fox BA; Moudgil T; Miller W; Haley D; Coffey T; Fisher B; Delanty-Miller L; Rymarchyk N; Kelly T; Crocenzi T; Bernstein E; Sanborn R; Urba WJ; Weinberg AD
Cancer Res; 2013 Dec; 73(24):7189-7198. PubMed ID: 24177180
[TBL] [Abstract][Full Text] [Related]
11. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.
Quezada SA; Peggs KS; Simpson TR; Shen Y; Littman DR; Allison JP
J Exp Med; 2008 Sep; 205(9):2125-38. PubMed ID: 18725522
[TBL] [Abstract][Full Text] [Related]
12. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
Hirschhorn D; Betof Warner A; Maniyar R; Chow A; Mangarin LM; Cohen AD; Hamadene L; Rizzuto GA; Budhu S; Suek N; Liu C; Houghton AN; Merghoub T; Wolchok JD
JCI Insight; 2021 Oct; 6(20):. PubMed ID: 34676831
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.
Tanaka A; Nishikawa H; Noguchi S; Sugiyama D; Morikawa H; Takeuchi Y; Ha D; Shigeta N; Kitawaki T; Maeda Y; Saito T; Shinohara Y; Kameoka Y; Iwaisako K; Monma F; Ohishi K; Karbach J; Jäger E; Sawada K; Katayama N; Takahashi N; Sakaguchi S
J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31704808
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
17. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.
Bos PD; Plitas G; Rudra D; Lee SY; Rudensky AY
J Exp Med; 2013 Oct; 210(11):2435-66. PubMed ID: 24127486
[TBL] [Abstract][Full Text] [Related]
18. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
[TBL] [Abstract][Full Text] [Related]
20. OX40 controls functionally different T cell subsets and their resistance to depletion therapy.
Kroemer A; Xiao X; Vu MD; Gao W; Minamimura K; Chen M; Maki T; Li XC
J Immunol; 2007 Oct; 179(8):5584-91. PubMed ID: 17911646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
